4D-150 in Patients With Diabetic Macular Edema

Running, not enrolling · Phase 2

Conditions studied: Diabetic Macular Edema, Diabetic Retinopathy

In brief

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Key facts

Study ID

NCT05930561

Run by

4D Molecular Therapeutics

People needed

72

Starts

2023-08-09

Expected to finish

2029-02-28

Last updated by the study team

2025-09-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age
• Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea; diagnosis of DME must be within 2 years of Screening
• CST ≥ 350 μm (Spectralis SD-OCT) in the study eye at Screening, confirmed by the independent reading center
• Demonstrate clinical response to on-study aflibercept injection in the study eye.
• Decreased visual acuity attributable primarily to DME
• BCVA in the study eye between 25 and 83 ETDRS letters, inclusive (\~20/320 and 20/25, respectively) at Screening
• Study eye amenable to IVT injection
• Sufficient clear ocular media, pupil dilation and fixation in the study eye to permit adequate imaging; ability to perform tests of visual and retinal function and structure; and ability to comply with other protocol-specified procedures
• Provide written informed consent

You may not qualify if…

• Macular edema in the study eye considered to be secondary to a cause other than DME
• Systemic anti-VEGF treatment (e.g. sunitinib, bevacizumab, pazopanib) within 6 months, or anticipated need for systemic anti-VEGF therapy during study participation
• Systemic corticosteroids (oral, intravenous, intramuscular, intra-articular) or other immunosuppressive medications within 3 months
• Received an investigational drug, agent, device, or therapy (ocular or non-ocular) in the 3 months (or at least 5 half-lives, whichever is longer) prior to 4D-150 administration (Day 1)
• Prior gene therapy (ocular or non-ocular) and/or ocular stem cell therapy in either eye
• Any concurrent ocular condition in the study eye that is likely to require surgical intervention (e.g. cataract surgery) during the 2 year (104 week) study duration
• Note: Other inclusion/exclusion criteria apply.

Where it is running

• Cumberland Valley Retina Consultants — Hagerstown, Maryland, United States
• Verum Research, LLC — Eugene, Oregon, United States
• Erie Retina Research — Erie, Pennsylvania, United States
• Austin Clinical Research — Austin, Texas, United States
• Piedmont Eye Center — Lynchburg, Virginia, United States
• Emanuelli Research and Development Center — Arecibo, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.